Tag: PDAC

Statistically significant and clinically meaningful improvement in overall survival (OS) and progression-free survival (PFS) has been achieved with liposomal irinotecan (Onivyde) plus 5-fluorouracil/leucovorin (5-FU) and oxaliplatin (NALIRIFOX) over gemcitabine plus nab-paclitaxel in patients with treatment-naïve metastatic pancreatic ductal adenocarcinoma (PDAC), results from the phase 3 NAPOLI 3 study (NCT04083235) show.1…

Laboratory Corporation of America Plasma Focus Labcorp has launched its Plasma Focus liquid biopsy test, which analyzes cell-free DNA to enable targeted therapy selection for patients with advanced or metastatic solid tumors. The test in intended for use in patients with non-small cell lung, colorectal, breast, esophageal, gastroesophageal junction, and…

On Track for September PDUFA Target Action Date on NDA for Motixafortide in Stem Cell Mobilization (SCM) for Autologous Transplantation in Multiple Myeloma (MM)  Rapidly Advancing U.S. Commercial Activities in Support of Potential September Launch  Announced Publication in Nature Medicine of GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and…

Introduction Pancreatic cancer (PC) is a malignant tumor with a very high mortality rate for which there is no effective treatment other than surgery.1,2 PC is prone to metastasis and invasion in the early stage, and there is no effective means for early detection. Most patients often have cancer metastasis…

PARIS and CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided an update on operational progress and reported financial results for the for the…

Scientists have created the first-of-its-kind personalized mRNA vaccine in an effort to combat pancreatic cancer.  Patients were enrolled in clinical trials to test this personalized approach to treat a type of pancreatic cancer known as pancreatic ductal adenocarcinoma (PDAC).  The approach to creating a cancer vaccine  Recent studies have found…

LIfT BioSciences has revealed preclinical data demonstrating that its immunomodulatory alpha neutrophil product (IMAN) showed potent killing of pancreatic cancer tumoroids.  The tumoroid originated from a patient with pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer. The patient was unresponsive to conventional chemotherapy treatment with Abraxane (nab-paclitaxel),…

Reported initial positive clinical data from first two cohorts of Phase II of ongoing Phase I/II study (COVALENT-111) of BMF-219, Biomea’s lead investigational, orally administered covalent menin inhibitor, as a novel, potentially disease-modifying treatment for patients with type 2 diabetes Continued enrolling four liquid tumor cohorts in ongoing Phase I…

Mechanistic studies of the EXTRA-CRISPR assay The assay is designed to be a tri-enzymatic cascade that exploits the unique nucleolytic cleavage activities of the CRISPR–Cas12a system to create a new exponential isothermal amplification mechanism based on the robust linear RCA assay. The assay starts with the hybridization of a padlock…

Pancreatic ductal adenocarcinoma (PDAC) is believed to arise from the accumulation of a series of somatic mutations and is also frequently associated with pancreatic intraepithelial neoplasia (PanIN) lesions. However, there is still debate as to whether the cell-type-of-origin of PanINs and PDACs in humans is acinar or ductal. As cell…

ResearchIn-Press PreviewCell biology Open Access | 10.1172/JCI165934 Grace Oh,1 Annie Wang,2 Lidong Wang,2 Jiufeng Li,2 Gregor Werba,1 Daniel Weissinger,1 Ende Zhao,2 Surajit Dhara,2 Rosmel E. Hernandez,2 Amanda Ackermann,2 Sarina Porcella,3 Despoina Kalfakakou,2 Igor Dolgalev,4 Emily A. Kawaler,2 Talia Golan,5 Theodore H. Welling,1 Agnel Sfeir,3 and Diane M. Simeone1 1Department of…

Expanded clinical development footprint of BMF-219, the company’s lead investigational, orally administered, covalent menin inhibitor, to eight liquid and solid tumor indications and type 2 diabetes across three ongoing clinical trials COVALENT-101 (Phase I study) enrolling four liquid tumor cohorts, each focused on distinct patient subsets of acute lymphocytic and…

This protocol will allow researchers to not only streamline their analysis pipeline, but it will also allow them to extract more information out of their organoid stream, thereby enhancing the translational relevance. The main advantage of this protocol is it combines a streamlined workflow with an automated and clinically relevant…

. 2023 Jan-Feb;56(1):42-49. doi: 10.1590/0100-3984.2022.0032-en. Affiliations Expand Affiliation 1 Hospital Vila Nova Star, Rede D’Or, São Paulo, SP, Brazil. Item in Clipboard Thiago Pereira Fernandes da Silva et al. Radiol Bras. 2023 Jan-Feb. Show details Display options Display options Format AbstractPubMedPMID . 2023 Jan-Feb;56(1):42-49. doi: 10.1590/0100-3984.2022.0032-en. Affiliation 1 Hospital Vila Nova…

Purple Biotech Ltd. has released new results from exploratory analyses conducted as part of a phase 1 dose escalation study that assessed the safety and tolerability of nivolumab and CM24, which is a monoclonal antibody.  Purple Biotech is a clinical-stage company developing first-in-class therapies that harness the tumor microenvironment (TME)…

Efficacy of POLθ inhibition in HR-deficient cancers requires CD8+ T cells. a, b K14-Cre-Brca1f/f;Trp53f/f TNBC tumors from syngeneic FVB/129P2 mice (VEH, n = 5; NVB, n = 7) (a), or Brca2 KO KPC PDAC tumors from syngeneic C57BL/6 mice (VEH, n = 7; NVB, n = 6) (b) were subjected to IHC for CD3, CD4, and CD8 expression….

Zev A. Wainberg, MD, professor of medicine, University of California, Los Angeles (UCLA), co-director, the UCLA GI Oncology Program, discusses the rationale behind the phase 3 NAPOLI 3 trial (NCT04083235) in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). The NAPOLI 3 trial evaluated liposomal irinotecan (Onivyde) plus 5-fluorouracil (5-FU), leucovorin,…

Register for FREE to listen to this article Thank you. Listen to this article using the player above. ✖ Want to listen to this article for FREE? Complete the form below to unlock access to ALL audio articles. Scientists at VCU Massey Cancer Center uncovered a previously…

Model for the functional interaction between Smad4 and Prdm16 during PDAC formation and progression. Credit: Journal of Cell Biology (2023). DOI: 10.1083/jcb.202203036 Scientists at VCU Massey Cancer Center have uncovered a previously unrecognized relationship between two sets of proteins that operate in tandem to fend off the growth of pancreatic…

1 Introduction Cancer is one of the world’s most serious threats to human health, with high morbidity and mortality rates, and according to the latest global data, 9.96 million patients will die from cancer in 2020 (1). Cancer is a genetic abnormal disease triggered by a long-term combination of multiple…

Emerging evidence indicates the critical roles of N6-methyladenosine (m6A) modification in human cancers. Herein, our work reported that a novel m6A-modified circRNA from the MYO1C gene, circMYO1C, upregulated in the pancreatic ductal adenocarcinoma (PDAC). Our findings demonstrated that circMYO1C is highly expressed in PDAC tissues. Functionally, circMYO1C promoted the proliferation…

Early detection (pancreatic cancer) cfMeDIP-seq, 5hmC sequencing LR elastic-net Hierarchical clustering, t-SNE, LR with elastic-net penalization Methylation (5mC-5hmC) 208 (72/136) 24-feature 5mC, 27-features 5hmC, 51-features combined model SML, UML Combined 5mC and 5hmC AUC of 0.997 (sensitivity 0.938, specificity 0.955) Median total reads: 17.4 M, 0.8 nonduplicate mapping rate pms.cd120.com/PDAC/index.html…

Taped outside of the lab of Dr. Christopher Kemp, a professor in the Human Biology Division, hangs a piece of paper with an earlier version of the Fred Hutch logo- a DNA helix integrated between an “H” with the slogan, “Advancing Knowledge, Saving Lives”. Russell Moser, a research scientist in…

Introduction Pancreatic cancer (PC) is one of the most aggressive and lethal cancers (1). Previous studies have shown that aging, environmental and behavioral changes are more closely related to the dramatic increase in the incidence of PC worldwide than genetic factors (2–5). A position paper published by the European Federation…

Introduction Most cases of pancreatic adenocarcinoma (PDAC) are diagnosed in the metastatic or locally advanced stage. It is the fourth leading cause of cancer death in the United States,1,2 with a 5-year overall survival (OS) around 10% in this country2 despite years of research and therapeutic development. For those patients…

Introduction Pancreatic ductal adenocarcinoma (PDAC) is a lethal gastrointestinal disease with increasing morbidity, which also has a growing impact on cancer-specific mortality worldwide.1 Nearly 40% of all PDAC cases are localized to the pancreas and characterized with the involvement of major vascular structures, leading to unresectable disease without metastases detected…

Possible biomarkers for prognosis and clinical outcomes were identified, through the use whole exome sequencing and RNA sequencing, as therapeutic targets for patients with pancreatic ductal adenocarcinoma (PDAC), according to a recent study. The study, published in Therapeutic Advances in Medical Oncology, also reconfirmed genomic landscapes, major driver mutations, and…

Using a temporal multi-omics approach, a team led by scientists from Heidelberg University has identified a protein involved in tumor metastasis that could serve as a new therapeutic cancer target. Metastasis is the leading cause of cancer-related mortality and the mechanistically least well-understood step of the tumor progression cascade. However,…